

Early Benefit Assessment Dossiers

Gaining global market access for your products requires expertise in widely varied and constantly changing reimbursement environments. Our experts have experience contributing to successful NICE and other HTA submissions and can help you achieve the best result for your product.


We provide strategic input into the development and presentation of robust and compelling value arguments and analyses of clinical and economic data. We are knowledgeable about NICE processes; we prepared the first successful submission under the STA process when it was initially launched.

We can develop all components required for your submissions, including CU models, BIMs, systematic reviews of clinical and economic evidence, and meta-analyses, as well as full and partial dossiers. We also assist sponsors with responses to NICE during the consultation process.

Our HTA submission experience includes:

- National Institute of Clinical Excellence (NICE) – UK
- Scottish Medicines Consortium (SMC) – Scotland
- All Wales Medicines Strategy Group (AWMSG) – Wales
- National Centre for Pharmacoeconomics (NCPE) – Ireland
- The Dental and Pharmaceutical Benefits Agency (TLV) – Sweden
- Pharmaceutical Benefits Advisory Committee (PBAC) – Australia
- Academy of Managed Care Pharmacy (AMCP) dossier – USA
- WellPoint (WP) dossier – USA
- Canadian Agency for Drugs and Technologies in Health (CADTH)
- Federal Joint Commission, Gemeinsamer Bundesausschuss (G-BA) - Germany

STA Process



¹ Submissions from manufacturer/sponsor, health care professionals, and patient/carer groups
² Evidence Review Group

³ Positive Committee for Human Medicinal Products opinion required to proceed
⁴ Appraisal consultation document

⁵ Final Appraisal Determinations
⁶ 15 working days to appeal

Contact Us:
info@rtihs.org
www.rtihs.org

Kati Copley-Merriman,
MS, MBA
Vice President, Outcomes,
kcmerriman@rti.org

Stephanie Earnshaw, PhD
Vice President, Health
Economics,
searnshaw@rti.org